PMC:7784786 / 10222-11788 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"381","span":{"begin":516,"end":524},"obj":"Gene"},{"id":"382","span":{"begin":1122,"end":1126},"obj":"Gene"},{"id":"383","span":{"begin":1199,"end":1203},"obj":"Gene"},{"id":"384","span":{"begin":1375,"end":1379},"obj":"Gene"},{"id":"385","span":{"begin":1384,"end":1389},"obj":"Gene"},{"id":"386","span":{"begin":1471,"end":1474},"obj":"Gene"},{"id":"387","span":{"begin":184,"end":191},"obj":"Species"},{"id":"388","span":{"begin":611,"end":618},"obj":"Species"},{"id":"389","span":{"begin":1046,"end":1053},"obj":"Species"},{"id":"390","span":{"begin":1345,"end":1352},"obj":"Species"},{"id":"391","span":{"begin":421,"end":427},"obj":"Chemical"},{"id":"392","span":{"begin":466,"end":477},"obj":"Chemical"},{"id":"393","span":{"begin":479,"end":498},"obj":"Chemical"},{"id":"394","span":{"begin":500,"end":511},"obj":"Chemical"},{"id":"395","span":{"begin":727,"end":737},"obj":"Chemical"},{"id":"396","span":{"begin":1307,"end":1317},"obj":"Chemical"},{"id":"397","span":{"begin":41,"end":49},"obj":"Disease"},{"id":"398","span":{"begin":218,"end":230},"obj":"Disease"},{"id":"399","span":{"begin":232,"end":249},"obj":"Disease"},{"id":"400","span":{"begin":251,"end":259},"obj":"Disease"},{"id":"401","span":{"begin":310,"end":315},"obj":"Disease"},{"id":"402","span":{"begin":330,"end":338},"obj":"Disease"},{"id":"403","span":{"begin":357,"end":372},"obj":"Disease"},{"id":"404","span":{"begin":376,"end":384},"obj":"Disease"},{"id":"405","span":{"begin":914,"end":934},"obj":"Disease"}],"attributes":[{"id":"A381","pred":"tao:has_database_id","subj":"381","obj":"Gene:3440"},{"id":"A382","pred":"tao:has_database_id","subj":"382","obj":"Gene:3569"},{"id":"A383","pred":"tao:has_database_id","subj":"383","obj":"Gene:3569"},{"id":"A384","pred":"tao:has_database_id","subj":"384","obj":"Gene:3553"},{"id":"A385","pred":"tao:has_database_id","subj":"385","obj":"Gene:7124"},{"id":"A386","pred":"tao:has_database_id","subj":"386","obj":"Gene:26503"},{"id":"A387","pred":"tao:has_database_id","subj":"387","obj":"Tax:9606"},{"id":"A388","pred":"tao:has_database_id","subj":"388","obj":"Tax:9606"},{"id":"A389","pred":"tao:has_database_id","subj":"389","obj":"Tax:9606"},{"id":"A390","pred":"tao:has_database_id","subj":"390","obj":"Tax:9606"},{"id":"A391","pred":"tao:has_database_id","subj":"391","obj":"MESH:D010100"},{"id":"A392","pred":"tao:has_database_id","subj":"392","obj":"MESH:D002443"},{"id":"A393","pred":"tao:has_database_id","subj":"393","obj":"MESH:C558899"},{"id":"A394","pred":"tao:has_database_id","subj":"394","obj":"MESH:D002738"},{"id":"A395","pred":"tao:has_database_id","subj":"395","obj":"MESH:C000597346"},{"id":"A396","pred":"tao:has_database_id","subj":"396","obj":"MESH:C000597346"},{"id":"A397","pred":"tao:has_database_id","subj":"397","obj":"MESH:C000657245"},{"id":"A398","pred":"tao:has_database_id","subj":"398","obj":"MESH:D006973"},{"id":"A399","pred":"tao:has_database_id","subj":"399","obj":"MESH:D003920"},{"id":"A400","pred":"tao:has_database_id","subj":"400","obj":"MESH:D005901"},{"id":"A401","pred":"tao:has_database_id","subj":"401","obj":"MESH:D003371"},{"id":"A402","pred":"tao:has_database_id","subj":"402","obj":"MESH:D003967"},{"id":"A404","pred":"tao:has_database_id","subj":"404","obj":"MESH:C000657245"},{"id":"A405","pred":"tao:has_database_id","subj":"405","obj":"MESH:D012128"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Patient 3: An 81-year old female, who is COVID-19 positive contact was not identified at the moment of hospitalization. She started symptoms on 2 April and entered the ICU on 5 April. Patient has a previous history of hypertension, diabetes mellitus, glaucoma and smoking habit. She was admitted with frequent cough, wheezing and diarrhea. The diagnosis of viral pneumonia by COVID-19 was confirmed by RT-PCR on 7 April. Oxygen support at 5 l/min and treatment with ceftriaxone, lopinavir–ritonavir, chloroquine and IFN α-2b was indicated. Chest images showed bilateral interstitial infiltration in both lungs. Patient condition was classified as severe, although she did not require invasive mechanical ventilation. A dose of itolizumab (200 mg) was given the day after her admission into the ICU. Two days after the antibody administration, together with the rest of the therapy, there was an improvement of the respiratory distress while the chest image showed a decrease of the alveolar interstitial infiltrate of both lungs (Figure 1C \u0026 D). Patient left the ICU after a favorable clinical and radiological evolution. IL-6 concentration was measured prior and after the antibody administration. IL-6 level at baseline was lower than in previous cases (30 pg/ml), but also decreased 48 h and 168 h after itolizumab infusion, in parallel with patient recovery (Figure 2A). IL-1 and TNF-α were untraceable before and 48 h after the antibody administration. Regarding to AST concentration, the values were in the normal range during the treatment period (Figure 2B)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T43","span":{"begin":218,"end":230},"obj":"Phenotype"},{"id":"T44","span":{"begin":232,"end":249},"obj":"Phenotype"},{"id":"T45","span":{"begin":251,"end":259},"obj":"Phenotype"},{"id":"T46","span":{"begin":310,"end":315},"obj":"Phenotype"},{"id":"T47","span":{"begin":317,"end":325},"obj":"Phenotype"},{"id":"T48","span":{"begin":330,"end":338},"obj":"Phenotype"},{"id":"T49","span":{"begin":363,"end":372},"obj":"Phenotype"},{"id":"T50","span":{"begin":914,"end":934},"obj":"Phenotype"}],"attributes":[{"id":"A43","pred":"hp_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A44","pred":"hp_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/HP_0000819"},{"id":"A45","pred":"hp_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/HP_0000501"},{"id":"A46","pred":"hp_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A47","pred":"hp_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/HP_0030828"},{"id":"A48","pred":"hp_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A49","pred":"hp_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A50","pred":"hp_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/HP_0002098"}],"text":"Patient 3: An 81-year old female, who is COVID-19 positive contact was not identified at the moment of hospitalization. She started symptoms on 2 April and entered the ICU on 5 April. Patient has a previous history of hypertension, diabetes mellitus, glaucoma and smoking habit. She was admitted with frequent cough, wheezing and diarrhea. The diagnosis of viral pneumonia by COVID-19 was confirmed by RT-PCR on 7 April. Oxygen support at 5 l/min and treatment with ceftriaxone, lopinavir–ritonavir, chloroquine and IFN α-2b was indicated. Chest images showed bilateral interstitial infiltration in both lungs. Patient condition was classified as severe, although she did not require invasive mechanical ventilation. A dose of itolizumab (200 mg) was given the day after her admission into the ICU. Two days after the antibody administration, together with the rest of the therapy, there was an improvement of the respiratory distress while the chest image showed a decrease of the alveolar interstitial infiltrate of both lungs (Figure 1C \u0026 D). Patient left the ICU after a favorable clinical and radiological evolution. IL-6 concentration was measured prior and after the antibody administration. IL-6 level at baseline was lower than in previous cases (30 pg/ml), but also decreased 48 h and 168 h after itolizumab infusion, in parallel with patient recovery (Figure 2A). IL-1 and TNF-α were untraceable before and 48 h after the antibody administration. Regarding to AST concentration, the values were in the normal range during the treatment period (Figure 2B)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T92","span":{"begin":0,"end":10},"obj":"Sentence"},{"id":"T93","span":{"begin":11,"end":119},"obj":"Sentence"},{"id":"T94","span":{"begin":120,"end":278},"obj":"Sentence"},{"id":"T95","span":{"begin":279,"end":339},"obj":"Sentence"},{"id":"T96","span":{"begin":340,"end":420},"obj":"Sentence"},{"id":"T97","span":{"begin":421,"end":539},"obj":"Sentence"},{"id":"T98","span":{"begin":540,"end":610},"obj":"Sentence"},{"id":"T99","span":{"begin":611,"end":716},"obj":"Sentence"},{"id":"T100","span":{"begin":717,"end":798},"obj":"Sentence"},{"id":"T101","span":{"begin":799,"end":1045},"obj":"Sentence"},{"id":"T102","span":{"begin":1046,"end":1121},"obj":"Sentence"},{"id":"T103","span":{"begin":1122,"end":1198},"obj":"Sentence"},{"id":"T104","span":{"begin":1199,"end":1374},"obj":"Sentence"},{"id":"T105","span":{"begin":1375,"end":1457},"obj":"Sentence"},{"id":"T106","span":{"begin":1458,"end":1566},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Patient 3: An 81-year old female, who is COVID-19 positive contact was not identified at the moment of hospitalization. She started symptoms on 2 April and entered the ICU on 5 April. Patient has a previous history of hypertension, diabetes mellitus, glaucoma and smoking habit. She was admitted with frequent cough, wheezing and diarrhea. The diagnosis of viral pneumonia by COVID-19 was confirmed by RT-PCR on 7 April. Oxygen support at 5 l/min and treatment with ceftriaxone, lopinavir–ritonavir, chloroquine and IFN α-2b was indicated. Chest images showed bilateral interstitial infiltration in both lungs. Patient condition was classified as severe, although she did not require invasive mechanical ventilation. A dose of itolizumab (200 mg) was given the day after her admission into the ICU. Two days after the antibody administration, together with the rest of the therapy, there was an improvement of the respiratory distress while the chest image showed a decrease of the alveolar interstitial infiltrate of both lungs (Figure 1C \u0026 D). Patient left the ICU after a favorable clinical and radiological evolution. IL-6 concentration was measured prior and after the antibody administration. IL-6 level at baseline was lower than in previous cases (30 pg/ml), but also decreased 48 h and 168 h after itolizumab infusion, in parallel with patient recovery (Figure 2A). IL-1 and TNF-α were untraceable before and 48 h after the antibody administration. Regarding to AST concentration, the values were in the normal range during the treatment period (Figure 2B)."}